Bausch + Lomb (NYSE:BLCO) CEO Purchases $251,958.00 in Stock

Key Points

• CEO Brent Saunders purchased 14,700 shares at an average price of $17.14 (totaling $251,958), bringing his direct ownership to 966,575 shares — a 1.54% increase.
• In the most recent quarter Bausch + Lomb reported $0.32 EPS (missing the $0.35 consensus) and $1.41B revenue (beating $1.38B) with revenue up 9.8% YoY but a negative net margin of 7.06%; shares traded around $17.12 with a market cap of $6.06B and a 52‑week range of $10.45–$18.92.
• Several firms raised price targets recently (e.g., Citi, RBC, HC Wainwright), but the consensus remains an average rating of Hold with an average target of $18.25 (four Buy, ten Hold, one Sell).

Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) CEO Brent Saunders acquired 14,700 shares of the stock in a transaction dated Friday, March 6th. The shares were bought at an average price of $17.14 per share, with a total value of $251,958.00. Following the completion of the transaction, the chief executive officer directly owned 966,575 shares of the company's stock, valued at $16,567,095.50. The trade was a 1.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Bausch + Lomb Trading Down 0.6%

Shares of Bausch + Lomb stock traded down $0.10 during midday trading on Tuesday, reaching $17.12. The company had a trading volume of 201,504 shares, compared to its average volume of 402,941. The stock has a fifty day moving average price of $17.28 and a 200 day moving average price of $16.17. Bausch + Lomb Corporation has a fifty-two week low of $10.45 and a fifty-two week high of $18.92. The firm has a market cap of $6.06 billion, a PE ratio of -16.78, a P/E/G ratio of 0.72 and a beta of 0.58. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.55 and a quick ratio of 1.04.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, February 18th. The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.03). The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.38 billion. Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The firm's revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.25 EPS. On average, equities analysts anticipate that Bausch + Lomb Corporation will post 0.74 earnings per share for the current year.

Institutional Investors Weigh In On Bausch + Lomb

A number of large investors have recently bought and sold shares of BLCO. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Bausch + Lomb by 729.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company's stock valued at $30,000 after purchasing an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of Bausch + Lomb by 104.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company's stock worth $38,000 after purchasing an additional 1,136 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Bausch + Lomb by 31.2% in the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company's stock valued at $101,000 after buying an additional 1,403 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Bausch + Lomb by 55.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company's stock valued at $132,000 after buying an additional 3,246 shares during the period. Finally, Focus Partners Wealth bought a new stake in Bausch + Lomb in the 3rd quarter valued at about $170,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BLCO. HC Wainwright boosted their target price on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company a "buy" rating in a report on Monday, February 23rd. Citigroup increased their price target on Bausch + Lomb from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, February 19th. Wells Fargo & Company lifted their price objective on Bausch + Lomb from $17.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 19th. Royal Bank Of Canada upped their target price on Bausch + Lomb from $19.00 to $21.00 and gave the company an "outperform" rating in a research report on Tuesday, January 27th. Finally, Barclays raised their target price on Bausch + Lomb from $17.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 19th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $18.25.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.